Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions

On December 9, 2025, Artera announced the commercial launch of the ArteraAI Prostate Test (Post-RP), a tool designed to help identify which patients with biochemical recurrence following radical prostatectomy may benefit from intensified salvage therapy.¹ Specifically, the multimodal artificial intelligence (MMAI) test provides prognostic insight into the potential benefit of adding short-term androgen deprivation therapy (ADT) to radiation.

In an interview with Urology Times®, Daniel Spratt, MD, a radiation oncologist at University Hospitals Seidman Cancer Center in Cleveland, Ohio, discussed the clinical challenges of managing biochemical recurrence and how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions.

According to Spratt, clinicians have long lacked a reliable tool to support decision-making in this setting—a gap the ArteraAI Prostate Test was developed to address.

Spratt explained, “This [test] uses [patients’] clinical and pathologic features as well as, very importantly, digital pathology, running an artificial intelligence algorithm to help us put all these features together to identify patients at low risk of developing recurrence and metastatic disease vs those patients at much higher risk.”

Data presented at the American Urological Association 2024 Annual Meeting demonstrated the accuracy of the test in estimating metastatic risk among patients with biochemical recurrence.²

“When you use this MMAI test, it's really profound. Those with a low MMAI score have a much lower risk of developing recurrence or metastatic disease. So, the benefit of hormone therapy is only a couple percent. It's not zero, but it's a much smaller benefit vs when you find a patient who has a high MMAI score, [where] you're talking about benefits of 20% or higher in terms of reductions in metastatic disease,” said Spratt.

REFERENCES

1. Artera debuts ArteraAI Prostate Test (Post‑RP), expanding its oncology portfolio. News release. Artera. December 9, 2025. Accessed January 1, 2025. https://artera.ai/news/artera-debuts-arteraai-prostate-test-post%E2%80%91rp-expanding-its-oncology-portfolio

2. New data validating the first AI-based biomarker to stratify risk of metastasis in radical prostatectomy patients with biochemical recurrence. News release. Artera. May 6, 2024. Accessed January 1, 2025. https://artera.ai/news/new-data-validating-the-first-ai-based-biomarker-to-stratify-risk-of-metastasis-in-radical-prostatectomy-patients-with-biochemical-recurrence